These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22591421)

  • 1. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Sehouli J; Alfaro V; González-Martín A
    Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
    J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
    Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
    Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
    BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Colombo N
    Future Oncol; 2017 Oct; 13(23s):23-29. PubMed ID: 29020821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
    Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
    Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
    Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
    Krasner CN; McMeekin DS; Chan S; Braly PS; Renshaw FG; Kaye S; Provencher DM; Campos S; Gore ME
    Br J Cancer; 2007 Dec; 97(12):1618-24. PubMed ID: 18000504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
    Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
    Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
    Fisher M; Gore M
    Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.